I also think this opens us up for a much more lucrative license agreement. Possibly the potential pharma that will take this on wanted exactly this.

The granting of this waiver now enables the Company to develop Brilacidin in a more focused manner in adult patient populations where Oral Mucositis has the greatest impact.